


Clovibactin TFA

Cat. No.:	HY-P10027A
Molecular Formula:	C ₄₃ H ₇₀ N ₁₀ O ₁₁ .xC ₂ HF ₃ O ₂
Sequence:	Phe-{d-Leu}-{d-Lys}-Ser-{Hyn}-Ala-Leu-Leu (Cyclic ester: Hyn5-Leu8)
Sequence Shortening:	F-{d-Leu}-{d-Lys}-S-{Hyn}-ALL (Cyclic ester: Hyn5-Leu8)
Target:	Antibiotic; Bacterial
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (Need ultrasonic)
-----------------	------------------------------------

BIOLOGICAL ACTIVITY

Description	Clovibactin TFA is the TFA salt form of Clovibactin (HY-P10027). Clovibactin TFA is an antibiotic for drug-resistant bacterial pathogens without detectable resistance. Clovibactin TFA inhibits cell wall synthesis by targeting pyrophosphate of peptidoglycan precursors ^[1] .
In Vitro	Clovibactin TFA inhibits Staphylococcus strains with MICs of 0.125-2 µg/mL ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Clovibactin TFA (20 mg/kg, iv, single dose) exhibits a pharmacokinetic profile with a C _{max} of 219.3 µg/mL, an AUC _{to last} of 31.9 µg·h/mL, t _{1/2} of 2 h, CL of 9.4 mL/kg/min and a V _{dss} of 189.8 mL/kg in mice model ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Shukla R, et al., A new antibiotic from an uncultured bacterium binds to an immutable target. bioRxiv [Preprint]. 2023 May 15:2023.05.15.540765.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA